» Articles » PMID: 24390350

Discovery and Saturation Analysis of Cancer Genes Across 21 Tumour Types

Overview
Journal Nature
Specialty Science
Date 2014 Jan 7
PMID 24390350
Citations 1675
Authors
Affiliations
Soon will be listed here.
Abstract

Although a few cancer genes are mutated in a high proportion of tumours of a given type (>20%), most are mutated at intermediate frequencies (2-20%). To explore the feasibility of creating a comprehensive catalogue of cancer genes, we analysed somatic point mutations in exome sequences from 4,742 human cancers and their matched normal-tissue samples across 21 cancer types. We found that large-scale genomic analysis can identify nearly all known cancer genes in these tumour types. Our analysis also identified 33 genes that were not previously known to be significantly mutated in cancer, including genes related to proliferation, apoptosis, genome stability, chromatin regulation, immune evasion, RNA processing and protein homeostasis. Down-sampling analysis indicates that larger sample sizes will reveal many more genes mutated at clinically important frequencies. We estimate that near-saturation may be achieved with 600-5,000 samples per tumour type, depending on background mutation frequency. The results may help to guide the next stage of cancer genomics.

Citing Articles

Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers.

Hyeon D, Nam D, Shin H, Jeong J, Jung E, Cho S Mol Cancer. 2025; 24(1):77.

PMID: 40087745 DOI: 10.1186/s12943-025-02256-3.


Pro-Apoptotic Effects of Anandamide in Human Gastric Cancer Cells Are Mediated by AKT and ERK Signaling Pathways.

Garcia-Hernandez V, Torres-Roman A, Ruiz-Garcia E, Santamaria A, Manzo-Merino J, Garcia-Lopez A Int J Mol Sci. 2025; 26(5).

PMID: 40076652 PMC: 11900069. DOI: 10.3390/ijms26052033.


Molecular Docking of Lactoferrin with Apoptosis-Related Proteins Insights into Its Anticancer Mechanism.

Angel-Lerma L, Carrillo-Campos J, Sianez-Estrada L, Siqueiros-Cendon T, Leon-Flores D, Espinoza-Sanchez E Int J Mol Sci. 2025; 26(5).

PMID: 40076649 PMC: 11899785. DOI: 10.3390/ijms26052023.


Thirty years of NRF2: advances and therapeutic challenges.

Zhang D Nat Rev Drug Discov. 2025; .

PMID: 40038406 DOI: 10.1038/s41573-025-01145-0.


AAV-based vectors for human diseases modeling in laboratory animals.

Aliev T, Yudkin D Front Med (Lausanne). 2025; 11:1499605.

PMID: 40007819 PMC: 11859266. DOI: 10.3389/fmed.2024.1499605.


References
1.
Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

2.
Vogelstein B, Papadopoulos N, Velculescu V, Zhou S, Diaz Jr L, Kinzler K . Cancer genome landscapes. Science. 2013; 339(6127):1546-58. PMC: 3749880. DOI: 10.1126/science.1235122. View

3.
Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

4.
Garraway L, Lander E . Lessons from the cancer genome. Cell. 2013; 153(1):17-37. DOI: 10.1016/j.cell.2013.03.002. View

5.
Zack T, Schumacher S, Carter S, Cherniack A, Saksena G, Tabak B . Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013; 45(10):1134-40. PMC: 3966983. DOI: 10.1038/ng.2760. View